SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...
Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...
Northwestern Medicine scientists have uncovered new details explaining how poxviruses manipulate host cells to enhance their ...
Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...
It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.
The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...
Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback